Cannabinoid therapy cuts PTSD nightmares in a landmark trial
TL;DR Summary
In a multicenter, double‑blind randomized trial, nightly dronabinol (THC) reduced PTSD‑related nightmares more than placebo over 10 weeks in 171 adults. The primary outcome (CAPS‑IV B2: nightmare frequency/intensity) favored dronabinol with a between‑group difference of −1.50 (CI −2.28 to −0.71) and a moderate effect size (Cohen’s d ≈ 0.65), supporting dronabinol as a potential pharmacotherapy for PTSD nightmares; safety was monitored during titration and maintenance, and data access is described in the publication.
- Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial Nature
- THC medication made PTSD nightmares disappear for more than a third of patients ScienceDaily
- THC, the cannabis active ingredient, can put an end to trauma-related nightmares Charité – Universitätsmedizin Berlin
- The PTSD Nightmare Drug No One Expected: What Dronabinol’s RCT Tells Us About CNS Trial Design The Clinical Trial Vanguard
- Could THC help cure nightmares tied to horrific memories? vtcng.com
Reading Insights
Total Reads
0
Unique Readers
5
Time Saved
27 min
vs 28 min read
Condensed
99%
5,528 → 73 words
Want the full story? Read the original article
Read on Nature